Brookline Capital Management Analyst Recommendations & Stock Picks

Name: Community Performance Rating
Item: Brookline Capital Management
Rating: 2.9
Author: MarketBeat

This page lists the most recent publicly-reported stock recommendations and ratings issued by analysts at Brookline Capital Management. These ratings and price targets were collected from public media reports and are believed to be accurate, but cannot be verified with 100% certainty. MarketBeat and its parent company are in no way affiliated with or endorsed by Brookline Capital Management.

Company	Date	Action	Brokerage	Analyst	Rating	Price Target	Impact on Price
NMTR 9 Meters Biopharma	5/25/2023	Downgraded by	Brookline Capital Management	Analyst K. Dolliver	Buy -> Hold		N/A
ONCT Oncternal Therapeutics	4/3/2023	Downgraded by	Brookline Capital Management	Analyst K. Dolliver	Buy -> Hold		Low
NMTR 9 Meters Biopharma	3/22/2023	Reiterated by	Brookline Capital Management	Analyst K. Dolliver	Buy		Low
APGN Apexigen	3/10/2023	Downgraded by	Brookline Capital Management	Analyst K. Dolliver	Buy -> Hold		Low
ONCT Oncternal Therapeutics	3/9/2023	Reiterated by	Brookline Capital Management	Analyst K. Dolliver	Buy		Low
DARE Daré Bioscience	2/14/2023	Reiterated by	Brookline Capital Management	Analyst K. Dolliver	Buy		Low

FUSN Fusion Pharmaceuticals	2/13/2023	Reiterated by	Brookline Capital Management	Analyst K. Dolliver	Buy		Low
HEPA Hepion Pharmaceuticals	1/31/2023	Reiterated by	Brookline Capital Management	Analyst K. Dolliver	Buy		Low
BCEL Atreca	1/20/2023	Reiterated by	Brookline Capital Management	Analyst K. Dolliver	Buy		Low
ECOR electroCore	1/12/2023	Reiterated by	Brookline Capital Management	Analyst K. Dolliver	Buy		N/A
APGN Apexigen	12/12/2022	Reiterated by	Brookline Capital Management	Analyst K. Dolliver	Buy		Low
IMNN Imunon	11/14/2022	Reiterated by	Brookline Capital Management	Analyst K. Dolliver	Buy		Low
NMTR 9 Meters Biopharma	10/25/2022	Reiterated by	Brookline Capital Management	Analyst K. Raja	Buy		Low
VXRT Vaxart	10/3/2022	Reiterated by	Brookline Capital Management	Analyst K. Dolliver	Buy		Low
OTLK Outlook Therapeutics	10/3/2022	Reiterated by	Brookline Capital Management	Analyst K. Dolliver	Buy		Low
NMTR 9 Meters Biopharma	10/3/2022	Reiterated by	Brookline Capital Management	Analyst K. Dolliver	Buy		Low
MNPR Monopar Therapeutics	10/3/2022	Reiterated by	Brookline Capital Management	Analyst K. Dolliver	Buy		Low
LSTA Lisata Therapeutics	10/3/2022	Reiterated by	Brookline Capital Management	Analyst K. Dolliver	Buy		Low
IMNN Imunon	10/3/2022	Reiterated by	Brookline Capital Management	Analyst K. Dolliver	Buy		Low
EDSA Edesa Biotech	10/3/2022	Reiterated by	Brookline Capital Management	Analyst K. Dolliver	Buy		Low
ATE Antibe Therapeutics	8/15/2022	Reiterated by	Brookline Capital Management	Analyst K. Dolliver	Buy		N/A
ARCT Arcturus Therapeutics	8/10/2022	Reiterated by	Brookline Capital Management	Analyst K. Raja	Buy		Low
BCEL Atreca	8/8/2022	Reiterated by	Brookline Capital Management	Analyst K. Raja	Buy		Low
ATBPF Antibe Therapeutics	6/30/2022	Reiterated by	Brookline Capital Management	Analyst K. Dolliver	Buy		N/A
VERU Veru	5/18/2022	Target Raised by	Brookline Capital Management	Analyst Kumaraguru Raja	Buy -> Buy	$29.00 -> $31.00	Medium
VRCA Verrica Pharmaceuticals	3/10/2022	Reiterated by	Brookline Capital Management	Analyst K. Dolliver	Buy		Medium
NTLA Intellia Therapeutics	3/7/2022	Upgraded by	Brookline Capital Management	Analyst L. Cann	Hold -> Buy	$91.00	High
CTIC CTI BioPharma	3/1/2022	Target Raised by	Brookline Capital Management	Analyst L. Cann	Buy -> Buy	$7.20 -> $12.00	High
CRSP CRISPR Therapeutics	2/14/2022	Reiterated by	Brookline Capital Management	Analyst Leah Rush	Buy	$143.00	High
NTLA Intellia Therapeutics	2/14/2022	Reiterated by	Brookline Capital Management	Analyst Leah Rush	Buy		Low
CRBU Caribou Biosciences	2/14/2022	Reiterated by	Brookline Capital Management	Analyst L. Cann	Buy		Medium
BCDA BioCardia	2/3/2022	Reiterated by	Brookline Capital Management	Analyst K. Raja	Buy		High
FUSN Fusion Pharmaceuticals	2/2/2022	Reiterated by	Brookline Capital Management	Analyst K. Dolliver	Buy		Medium
ICCM IceCure Medical	2/1/2022	Reiterated by	Brookline Capital Management	Analyst K. Dolliver	Buy		Low
HEPA Hepion Pharmaceuticals	1/26/2022	Reiterated by	Brookline Capital Management	Analyst K. Raja	Buy		Low
DARE Daré Bioscience	1/19/2022	Reiterated by	Brookline Capital Management	Analyst K. Raja	Buy		High
PROC Procaps Group	12/14/2021	Reiterated by	Brookline Capital Management	Analyst Kemp Dolliver	Buy	$13.00	Low
PNT POINT Biopharma Global	12/1/2021	Reiterated by	Brookline Capital Management	Analyst Kemp Dolliver	Buy	$23.00	Medium
CTIC CTI BioPharma	11/15/2021	Reiterated by	Brookline Capital Management	Analyst L. Cann	Buy		High
NOVN Novan	10/19/2021	Reiterated by	Brookline Capital Management	Analyst Kemp Dolliver	Buy	$16.00	Medium

KYMR Kymera Therapeutics	10/13/2021	Reiterated by	Brookline Capital Management	Analyst Leah Rush Cann	Buy	$80.00	Medium
FBRX Forte Biosciences	9/3/2021	Reiterated by	Brookline Capital Management	Analyst K. Raja	Hold		Low
VERU Veru	8/27/2021	Reiterated by	Brookline Capital Management	Analyst K. Raja	Buy		Medium
SCYX SCYNEXIS	8/24/2021	Reiterated by	Brookline Capital Management	Analyst K. Raja	Buy		Low
BCEL Atreca	7/29/2021	Reiterated by	Brookline Capital Management	Analyst K. Raja	Buy		High
CCCC C4 Therapeutics	6/25/2021	Reiterated by	Brookline Capital Management	Analyst Leah Rush Cann	Buy		High
ATE Antibe Therapeutics	6/3/2021	Reiterated by	Brookline Capital Management	Analyst K. Dolliver	Buy		N/A
ATBPF Antibe Therapeutics	6/3/2021	Reiterated by	Brookline Capital Management	Analyst K. Dolliver	Buy		Medium
MNPR Monopar Therapeutics	5/25/2021	Reiterated by	Brookline Capital Management	Analyst K. Raja	Buy		Medium
BIOX Bioceres Crop Solutions	5/7/2021	Reiterated by	Brookline Capital Management	Analyst K. Dolliver	Buy		N/A
SQZ SQZ Biotechnologies	3/30/2021	Reiterated by	Brookline Capital Management	Analyst L. Cann	Buy		N/A
ONCT Oncternal Therapeutics	3/30/2021	Reiterated by	Brookline Capital Management	Analyst K. Raja	Buy	$16.00	High
NMTR 9 Meters Biopharma	3/25/2021	Reiterated by	Brookline Capital Management	Analyst K. Raja	Buy		High
MRNA Moderna	2/26/2021	Target Raised by	Brookline Capital Management		Buy	$180.00 -> $205.00	Low
XFOR X4 Pharmaceuticals	12/17/2020	Initiated by	Brookline Capital Management	Analyst L. Cann	Buy	$21.00	High
VERU Veru	12/14/2020	Target Raised by	Brookline Capital Management	Analyst K. Raja		$13.00 -> $17.00	High
SYRS Syros Pharmaceuticals	11/10/2020	Initiated by	Brookline Capital Management	Analyst L. Cann	Buy	$190.00	Low
CTIC CTI BioPharma	10/23/2020	Initiated by	Brookline Capital Management	Analyst L. Cann	Buy	$7.00	Medium
ECOR electroCore	10/23/2020	Initiated by	Brookline Capital Management	Analyst S. Yanchus	Buy	$75.00	Low
AWH Aspira Women's Health	10/14/2020	Reiterated by	Brookline Capital Management	Analyst S. Yanchus	Buy		High
AWH Aspira Women's Health	10/14/2020	Reiterated by	Brookline Capital Management	Analyst S. Yanchus	Buy		High
MEIP MEI Pharma	10/12/2020	Reiterated by	Brookline Capital Management	Analyst L. Cann	Buy		Medium
DMTK DermTech	9/11/2020	Initiated by	Brookline Capital Management	Analyst S. Yanchus	Buy		High
MDNA Medicenna Therapeutics	8/24/2020	Reiterated by	Brookline Capital Management	Analyst K. Raja	Buy		Medium
FBRX Forte Biosciences	8/28/2020	Initiated by	Brookline Capital Management	Analyst K. Raja	Buy	$90.00	Low
HUGE FSD Pharma	8/20/2020	Reiterated by	Brookline Capital Management	Analyst K. Raja	Buy		Low
HUGE FSD Pharma	8/20/2020	Initiated by	Brookline Capital Management		Buy	$11.00	N/A
KURA Kura Oncology	8/16/2020	Reiterated by	Brookline Capital Management	Analyst L. Cann	Buy		Low
NMTR 9 Meters Biopharma	8/18/2020	Initiated by	Brookline Capital Management	Analyst S. Yanchus	Buy	$100.00	High
VERU Veru	8/14/2020	Reiterated by	Brookline Capital Management	Analyst K. Raja	Buy		Low
ARCT Arcturus Therapeutics	8/11/2020	Reiterated by	Brookline Capital Management	Analyst K. Raja	Buy		Low
ATE Antibe Therapeutics	7/15/2020	Reiterated by	Brookline Capital Management	Analyst S. Yanchus	Buy		N/A
MRNA Moderna	7/13/2020	Reiterated by	Brookline Capital Management	Analyst L. Cann	Buy	$95.00	High
ASRT Assertio	6/3/2020	Initiated by	Brookline Capital Management		Buy	$3.50	Low
OTLK Outlook Therapeutics	5/5/2020	Initiated by	Brookline Capital Management	Analyst K. Raja	Buy		High
DARE Daré Bioscience	4/28/2020	Initiated by	Brookline Capital Management	Analyst S. Yanchus	Buy	$7.50	High
EDSA Edesa Biotech	3/30/2020	Initiated by	Brookline Capital Management	Analyst K. Raja	Buy	$10.00	High
CLPT ClearPoint Neuro	3/11/2020	Reiterated by	Brookline Capital Management	Analyst S. Yanchus	Buy		High
ARMP Armata Pharmaceuticals	3/13/2020	Reiterated by	Brookline Capital Management	Analyst K. Raja	Buy		High
CLPT ClearPoint Neuro	3/12/2020	Initiated by	Brookline Capital Management		Buy	$15.00	N/A
MNPR Monopar Therapeutics	2/19/2020	Initiated by	Brookline Capital Management	Analyst K. Raja	Buy	$42.00	High
BIOX Bioceres Crop Solutions	2/4/2020	Reiterated by	Brookline Capital Management	Analyst S. Yanchus	Buy		N/A
BCDA BioCardia	11/26/2019	Reiterated by	Brookline Capital Management	Analyst K. Raja	Buy		Low
BCDA BioCardia	11/26/2019	Initiated by	Brookline Capital Management		Buy	$22.00	Low
MDNA Medicenna Therapeutics	11/19/2019	Reiterated by	Brookline Capital Management		Buy	C$4.00	N/A
BCEL Atreca	8/20/2019	Reiterated by	Brookline Capital Management	Analyst K. Raja	Buy		High
SCYX SCYNEXIS	8/19/2019	Reiterated by	Brookline Capital Management	Analyst K. Raja	Buy		High
VXRT Vaxart	8/15/2019	Initiated by	Brookline Capital Management	Analyst K. Raja	Buy	$6.00	Low
VERU Veru	7/29/2019	Initiated by	Brookline Capital Management	Analyst K. Raja	Buy	$12.00	High
NHWK NightHawk Biosciences	7/29/2019	Initiated by	Brookline Capital Management	Analyst K. Raja	Buy	$56.00 -> $56.00	High

CLRB Cellectar Biosciences	7/29/2019	Initiated by	Brookline Capital Management	Analyst K. Raja	Buy	$60.00 -> $60.00	High
ARCT Arcturus Therapeutics	7/24/2019	Reiterated by	Brookline Capital Management	Analyst K. Raja	Buy		High
SCYX SCYNEXIS	1/4/2019	Reiterated by	Brookline Capital Management	Analyst K. Raja	Buy		High
CLRB Cellectar Biosciences	11/20/2018	Reiterated by	Brookline Capital Management	Analyst K. Raja	Buy		Low
ARCT Arcturus Therapeutics	9/27/2018	Reiterated by	Brookline Capital Management	Analyst K. Raja	Buy		Low
NHWK NightHawk Biosciences	8/1/2018	Reiterated by	Brookline Capital Management	Analyst K. Raja	Buy		Low
TNXP Tonix Pharmaceuticals	7/27/2018	Downgraded by	Brookline Capital Management	Analyst K. Raja	Buy -> Hold		Low
TNXP Tonix Pharmaceuticals	5/1/2018	Reiterated by	Brookline Capital Management	Analyst K. Raja	Buy		Low

MarketBeat Community Rating for Brookline Capital Management

Community Ranking:		2.9 out of 5 ( 2.9 of 5 stars)
Outperform Votes:		20,360 (Vote Outperform)
Underperform Votes:		15,165 (Vote Underperform)
Total Votes:		35,525

MarketBeat's community ratings are surveys of what our community members think about Brookline Capital Management and other research firms. Vote "Outperform" if you believe Brookline Capital Management's recommendations will outperform the S&P 500 over the long term. Vote "Underperform" if you believe Brookline Capital Management's recommendations will underperform the S&P 500 over the long term. You may vote once every thirty days.

Stock Ratings Reports and Tools

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

Ratings for Popular Stocks:

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Brookline Capital Management Analyst Recommendations & Stock Picks

MarketBeat Community Rating for Brookline Capital Management

Stock Ratings Reports and Tools

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info